Pomolide (Pomalidomide)

pomalidomide 3 mg capsule, 14 · ORAL · PBS code 12666P

AUTHORITY_REQUIRED

What it costs

AU$706.08 PBS-determined price per 14 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

• First listed on the PBS: 2022-10-01.
• Repeats: 2.
• PBS program: HB.

Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Multiple myeloma

Initial treatment with triple therapy (this drug, bortezomib and dexamethasone)

The condition must be confirmed by a histological diagnosis; AND

The treatment must form part of triple combination therapy limited to: (i) this drug, (ii) bortezomib, (iii) dexamethasone; AND

Patient must have progressive disease after at least one prior therapy that is either: (i) lenalidomide monotherapy, (ii) contains lenalidomide; AND

Patient must have undergone or be ineligible for a stem cell transplant.

Progressive disease is defined as at least 1 of the following:

(a) at least a 25% increase and an absolute increase of at least 5 g per L in serum M protein (monoclonal protein); or

(b) at least a 25% increase in 24-hour urinary light chain M protein excretion, and an absolute increase of at least 200 mg per 24 hours; or

(c) in oligo-secretory and non-secretory myeloma patients only, at least a 50% increase in the difference between involved free light chain and uninvolved free light chain; or

(d) at least a 25% relative increase and at least a 10% absolute increase in plasma cells in a bone marrow aspirate or on biopsy; or

(e) an increase in the size or number of lytic bone lesions (not including compression fractures); or

(f) at least a 25% increase in the size of an existing or the development of a new soft tissue plasmacytoma (determined by clinical examination or diagnostic imaging); or

(g) development of hypercalcaemia (corrected serum calcium greater than 2.65 mmol per L not attributable to any other cause).

Oligo-secretory and non-secretory patients are defined as having active disease with less than 10 g per L serum M protein.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Multiple myeloma

Continuing treatment with triple therapy (this drug, bortezomib and dexamethasone)

Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND

The treatment must form part of triple combination therapy limited to: (i) this drug, (ii) bortezomib, (iii) dexamethasone; AND

Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition.